0.7188
+0.0189
+(2.70%)
At close: April 10 at 4:00:01 PM EDT
0.7450
+0.03
+(3.64%)
Pre-Market: 8:00:00 AM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,287
9,287
5,490
1,245
14,941.3700
Operating Expense
50,880
50,880
57,482
54,747
58,653.4430
Operating Income
-41,593
-41,593
-51,992
-53,502
-43,712.0730
Net Non Operating Interest Income Expense
826
826
1,416
215
45.8980
Other Income Expense
93
93
-157
277
--
Pretax Income
-40,674
-40,674
-50,733
-53,010
-43,666.1750
Tax Provision
--
--
--
--
495
Net Income Common Stockholders
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Diluted NI Available to Com Stockholders
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Basic EPS
-0.91
-0.72
-1.11
-1.49
-1.41
Diluted EPS
-0.91
-0.72
-1.11
-1.49
-1.41
Basic Average Shares
49,518.9380
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Diluted Average Shares
49,518.9380
56,328.3480
45,754.7940
35,649.1340
31,285.4180
Total Operating Income as Reported
-41,500
-41,500
-52,149
-53,225
-43,712.0730
Rent Expense Supplemental
--
--
716
899
--
Total Expenses
50,880
50,880
57,482
54,747
58,653.4430
Net Income from Continuing & Discontinued Operation
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Normalized Income
-40,767
-40,767
-50,576
-53,287
-44,161.1750
Interest Income
1,622
1,622
2,661
928
45.8980
Interest Expense
796
796
1,245
713
--
Net Interest Income
826
826
1,416
215
45.8980
EBIT
-39,878
-39,878
-49,488
-52,297
-43,666.1750
EBITDA
-37,528
-37,528
-46,052
-50,491
-43,666.1750
Reconciled Depreciation
2,350
2,350
3,436
1,806
-1,777.9850
Net Income from Continuing Operation Net Minority Interest
-40,674
-40,674
-50,733
-53,010
-44,161.1750
Total Unusual Items Excluding Goodwill
93
93
-157
277
--
Total Unusual Items
93
93
-157
277
--
Normalized EBITDA
-37,621
-37,621
-45,895
-50,768
-43,666.1750
Tax Rate for Calcs
--
--
--
--
0.0003
12/31/2021 - 1/2/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RNTX Rein Therapeutics Inc.
1.5600
+7.59%
ACTU Actuate Therapeutics, Inc. Common stock
7.11
-3.72%
EXOZ eXoZymes, Inc.
11.77
+0.43%
COYA Coya Therapeutics, Inc.
4.9300
-5.92%
INAB IN8bio, Inc.
0.1471
-3.67%
APTO Aptose Biosciences Inc.
1.7100
0.00%
MOLN Molecular Partners AG
3.7900
+6.76%
TRVI Trevi Therapeutics, Inc.
5.28
-2.22%
LTRN Lantern Pharma Inc.
3.0400
+3.40%
DMAC DiaMedica Therapeutics Inc.
3.5100
-5.14%